title: Shock block for improved immunotherapy.
abstract: Cancer cells use heat shock proteins (HSP) to stabilize growth/survival-associated client proteins such as receptor tyrosine kinases (RTKs), in vivo. Our recent work suggests that chemical HSP90 inhibitors combined with a vaccination strategy targeting HSP90 client proteins that are (over)expressed in the tumor microenvironment yields superior therapeutic benefit.
authors.affiliation: Department of Immunology; University of Pittsburgh School of Medicine; Pittsburgh, PA USA ; Department of Dermatology; University of Pittsburgh School of Medicine; Pittsburgh, PA USA.
authors.forename: Aparna
authors.initials: A
authors.lastname: Rao
authors.forename: Devin B
authors.initials: DB
authors.lastname: Lowe
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Storkus